MedWatch

New EMA powers have come into force

The European Medicine Agency’s new role in European crisis preparedness was tested during the Covid-19 pandemic, and has now been made permanent.

Photo: KAI PFAFFENBACH/REUTERS / X00446

On March 1, EU Regulation to extend the European Medicines Agency’s (EMA) mandate came into effect, meaning that the agency’s more improvised role during the Covid-19 pandemic has now been set in stone.

The EMA ”is now responsible for monitoring medicine shortages that might lead to a crisis situation,” the agency writes in a news release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs